Weight Loss Drugs Like Ozempic Prove the Sickness at the Heart of the NHS
Most users of GLP-1 agonists like Ozempic need to stay on them long-term to keep pound off. So is medicine promoting an addicition?
Condie Carmack
Carolyn Hax: Weight loss praise turns judgmental upon mention of GLP-1 drugs
Losing weight after a years-long struggle, this letter writer gave credit to the method — then came the judgmental comments.
Doctor Exposes Long-Term Effects Of Ozempic Side Effect You Might Not Know About
Most people would agree they could shed a few pounds. Not everyone, however, is prepared to stick to a diet or put in the time at the gym. They’d rather take a shortcut, and one of those is Ozempic, hailed by influencers and celebrities as a miracle medicine. Now a doctor has issued a warning, … Read more
Weight-Loss Drugs’ Environmental Cost
Experts warn that current methods of making the peptide drugs are environmentally unfriendly April 28, 2024 by Aayushi Pratap Chemical & Engineering News, Volume 102, Issue 13 This article explores the significant environmental challenges associated with the rapidly increasing production of popular peptide-based weight-loss drugs like Wegovy and Zepbound. It highlights that current manufacturing methods, primarily solid-phase peptide … Read more
Gastric Bypass in a Pill Could Help Weight Loss Without Surgery or GLP-1 Side Effects
Learn about SYNT-101, the emerging treatment for obesity that combines the best of two proven methods.
FDA Accepts Novo Nordisk’s Application for Oral Wegovy: 5 Things to Know
A Wegovy weight loss pill from Novo Nordisk is forthcoming, providing an alternative to injectable GLP-1 drugs. Mads Claus Rasmussen/Ritzau Scanpix/AFP via Getty Images Federal regulators have accepted Novo Nordisk’s application to produce a pill version of its injectable weight loss medication Wegovy. Experts say an oral medication might be easier for people to use, … Read more
GLP-1s and Acute Pancreatitis; Yoga for IBS? MASLD Tied to Early-Onset Colon Cancer
(MedPage Today) — GLP-1 receptor agonists for patients with diabetes was not associated with an increased risk for acute pancreatitis, a multicenter analysis found. (American Journal of Gastroenterology) Allogeneic hematopoietic stem cell transplant…
Risk of Obesity-Related Cancer Similar for GLP-1 Receptor Agonists and Bariatric Surgery
THURSDAY, May 15, 2025 — Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) may cut the risk of obesity-related cancer (ORC) in patients being treated for diabetes and obesity, according to a study published online May 11 in…
GLP-1 reduces adverse cardiac events before weight loss: 3 notes
Adult patients taking Wegovy saw a reduced risk of experiencing a major adverse cardiovascular event within the first three months of treatment, according to a secondary analysis of the drug’s clinical trial data, presented May 12 at the European Congress on Obesity. Here are three notes from the secondary analysis: The “Semaglutide and Cardiovascular Outcomes … Read more